Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HMGB1 in sepsis.

Ulf Andersson1, Kevin J Tracey

  • 1Department of Woman and Child Health, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden. ulf@mbox313.swipnet.se

Scandinavian Journal of Infectious Diseases
|November 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vagus nerve control of HMGB1 accessibility: a bioelectronic strategy for inflammation and pain.

Bioelectronic medicine·2026
Same author

Bringing the Hospital to the Adult Patient: A Qualitative Study of Patients' and Relatives' Experiences of Mobile Emergency Care at Home.

Scandinavian journal of caring sciences·2026
Same author

A comparative analysis of HMGB1 and pCTS-L immunomodulatory properties in human peripheral blood mononuclear cells.

Frontiers in immunology·2026
Same author

Repurposing a detrimental antibody epitope as targeted therapeutics for sepsis and rheumatoid arthritis.

Military Medical Research·2026
Same author

Central neurons encode interleukin-1β signals and mediate stress-induced inflammation.

The Journal of experimental medicine·2026
Same author

Non-invasive identification of brain signatures of acute liver injury.

Theranostics·2026
Same journal

Fas-Ligand Mediated Apoptosis in Severe Sepsis and Shock.

Scandinavian journal of infectious diseases·2017
Same journal

Lipopolysaccharide-inducible Gene Expression Profile in Human Monocytes.

Scandinavian journal of infectious diseases·2017
Same journal

Fatal varicella pneumonia.

Scandinavian journal of infectious diseases·2015
Same journal

Wissler's Syndrome Associated with Parainfluenza 2 Infection.

Scandinavian journal of infectious diseases·2015
Same journal

Contamination of smears with "sergentella spiroides".

Scandinavian journal of infectious diseases·2015
Same journal

Recrudescent typhus: fluctuations in titers of complement-fixing and microagglutinating antibodies to rickettsia prowazeki in persons with a history of epidemic typhus.

Scandinavian journal of infectious diseases·2015
See all related articles

High-mobility group box 1 (HMGB1) functions as a cytokine, mediating inflammatory responses and delayed lethality in conditions like sepsis. Blocking HMGB1 offers a therapeutic window for treating lethal sepsis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • High-mobility group box 1 (HMGB1) is known for nuclear DNA binding and gene transcription roles.
  • Recent findings highlight HMGB1's extracellular cytokine activity, driving inflammatory responses.

Purpose of the Study:

  • To define HMGB1's role as a cytokine in inflammatory processes.
  • To explore HMGB1's mechanisms of action and therapeutic potential in sepsis.

Main Methods:

  • Investigated HMGB1's pro-inflammatory effects on monocytes/macrophages.
  • Analyzed HMGB1's role in animal models of endotoxemia, sepsis, and arthritis.
  • Examined HMGB1 signaling via the receptor for advanced glycation end-products (RAGE).

Main Results:

Related Experiment Videos

  • HMGB1 stimulates pro-inflammatory responses and mediates delayed lethality in inflammatory models.
  • HMGB1 is actively secreted or passively released, integrating inflammatory responses to cell injury.
  • HMGB1 acts as a late-acting cytokine, appearing extracellularly 8-12 hours post-stimulus.

Conclusions:

  • HMGB1 is a critical cytokine in innate immunity and delayed inflammatory responses.
  • Targeting HMGB1 blockade presents therapeutic opportunities, with effectiveness shown up to 24 hours post-sepsis induction.